1098 completed, 497 terminated, 469 recruiting, 240 active not recruiting. 2736 Phase 1, 1012 Phase 2.
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Antigen-specific T Cells Against Lung Cancer Lung cancer-specific T cells - Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-08-26 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-04-01 | 2026-10-28 |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Not yet recruiting | Xemed LLC | 10 | 2027-03-01 | 2026-09-01 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 89 | 2026-12-01 | 2026-02-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 338 | 2026-11-15 | 2026-10-23 |
| A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer HS-20093, Ivonescimab, Chemotherapy - Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 102 | 2026-11-10 | 2026-10-27 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-04 | 2026-10-30 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-04 | 2026-10-30 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-04 | 2026-10-30 |
| Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 78 | 2026-11-01 | 2026-10-26 |
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
Showing 20 of 2736. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (1972) · Lung Neoplasms (866) · Colorectal Neoplasms (405) · Small Cell Lung Carcinoma (397) · Breast Neoplasms (355) · Neoplasms (349) · Melanoma (341) · Ovarian Neoplasms (327) · Pancreatic Neoplasms (271) · Neoplasm Metastasis (260) · Squamous Cell Carcinoma of Head and Neck (256) · Stomach Neoplasms (245) · Carcinoma, Renal Cell (231) · Triple Negative Breast Neoplasms (196) · Head and Neck Neoplasms (172)
Neoplasms by Site (2713) · Respiratory Tract Neoplasms (2706) · Respiratory Tract Diseases (2687) · Lung Diseases (2660) · Neoplasms (2387) · Bronchial Neoplasms (2215) · Carcinoma, Bronchogenic (2214) · Lung Neoplasms (1844) · Neoplasms by Histologic Type (1058) · Neoplasms, Glandular and Epithelial (888) · Digestive System Diseases (769) · Digestive System Neoplasms (761) · Skin and Connective Tissue Diseases (729) · Skin Diseases (724)
pembrolizumab (276) · Carboplatin (238) · Cisplatin (185) · Pemetrexed (165) · Paclitaxel (138) · Nivolumab (136) · Docetaxel (115) · Radiotherapy (105) · Erlotinib Hydrochloride (94) · Gemcitabine (93) · Bevacizumab (63) · Etoposide (63) · Cyclophosphamide (62) · osimertinib (61) · atezolizumab (58)
National Cancer Institute (NCI) (112) · Pfizer (60) · M.D. Anderson Cancer Center (57) · Memorial Sloan Kettering Cancer Center (54) · Novartis Pharmaceuticals (51) · AstraZeneca (49) · Eli Lilly and Company (43) · AbbVie (30) · Boehringer Ingelheim (30) · Bristol-Myers Squibb (30) · Merck Sharp & Dohme LLC (23) · Amgen (21) · Incyte Corporation (21) · GlaxoSmithKline (20) · H. Lee Moffitt Cancer Center and Research Institute (20)
United States (1795) · China (472) · Spain (337) · France (247) · Canada (239) · Australia (232) · South Korea (218) · United Kingdom (212) · Japan (189) · Italy (159) · Germany (145) · Taiwan (141) · Belgium (132) · Netherlands (118) · Poland (75)
PMID 39462179, PMID 40056080, PMID 42820295, PMID 22473314, PMID 23578144, PMID 24739759, PMID 25747273, PMID 27863201, PMID 29178442, PMID 29381826, PMID 29748847, PMID 30171779, PMID 31527168, PMID 31706099, PMID 31996395, PMID 33595690, PMID 34385708, PMID 34405547, PMID 34408488, PMID 35537408, PMID 35962934, PMID 36537204, PMID 37590355, PMID 37934000, PMID 38172595, PMID 38321811, PMID 39113428, PMID 40443562, PMID 41037823, PMID 42580817, PMID 11099318, PMID 11410496, PMID 11487589, PMID 11948464, PMID 12056703, PMID 12631594, PMID 14679114, PMID 14967075, PMID 15013589, PMID 15033677, PMID 15246197, PMID 15258838, PMID 15328179, PMID 15457249, PMID 15667949, PMID 15886314, PMID 15890573, PMID 16096702, PMID 16170174, PMID 16246975
2023 (55), 2016 (38), 2017 (32), 2019 (30), 2015 (24), 2025 (24), 2014 (20), 2018 (19), P30CA093373 (10), P30CA033572 (9), UM1CA186717 (8), 2008 (7), 2009 (7), P30CA016672 (6), P30CA072720 (6)